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In vitro methods have shown that
both animal and human lymphoid cells
often have an effective cytotoxicity against
autochthonous tumour cells (for a review
see Hellstr6m and Hellstrdnm, 1974).
Total or partial block of lymphoid cell
mediated immunity, however, may be
caused bv serum factors of tumour
bearing hosts. 78 immunoglobulin (Hell-
str6m and Hellstr6m, 1969). antigen de-
tached from the cell membrane (Sjogren et
al., 1971; Currie and Basham, 1972) or
complexes consisting of tumour specific
antigen-antibody combinations (Baldwin,
Price and Robins, 1972, 1973; Thomson,
Eccles and Alexander, 1973) are thought to
be responsible.
Serum factors may thus be deter-
minant elements in the tumour-host
relationship. In vivo studies, however,
have employed special systems, allo-
geneic or immunized animals, hyper-
immune sera (for a review see Voisin,
1971), irradiated mice (Vaage,. 1973) and
spontaneously regressing tumours (Pierce,
1971). These and other findings (Bansal,
Hargreaves and Sj6gren. 1972) are not
reliable for a clarification of what in
vivo significance blocking factors might
have. The present paper reports a study
of the effect of the pre-existence and re-
peated administration of serum from
non-immunomanipulated tumour bearing
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mnice and/or solubilized membrane anti-
gens, on the taking and growth of two
different antigenic tumours in a syngeneic
systemn.
MATERIALS AND METHODS
Groups of mice were randomized from
12-wreek old, 20-22 g, imbred male Balb/c
mice from the National Institutes of Health,
U.S.A., strain. Two syngeneic tumours were
used: a chemically induced IgA plasma-
cytoma, MOPC-460 (Potter, 1967) and a
spontaneous adenocarcinoma (ADK-lt) that
had been maintained for 12 generations
before use in the experiment reported. The
tumours were transmitted by subcutaneous
inoculations of 0-2 ml of living teased cells
suspended in Hanks' solution. The
injection site was palpated for the presence
of tumour every other day and growth
rates measured writh a caliper. The mem-
brane antigens wvere prepared by freezing-
thawing and suspending neoplastic or normal
liver cells in 0 05 mol/l NaCI 0-01 mol/l
phosphate buffer, pH 7 3, 1 mmol/l ZnC]2.
Cells were then disrupted with an Ultra-
Turrax homogenizer and diluted 1: 1 with
60% (w/v) sucrose and centrifuged at 400 g
for 30 min over a cushion of 450o sucrose
in H20. The upper layer was harvested
and spun at 25,000 g for 25 min. The
pellet, shown, by electron microscopy to
contain large plasma membrane vesicles
mainly contaminated with endoplasmic reti-
culum, was suspended in 10 volumes of
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100 sodium deoxycholate (DOC) in barbitone
buffer 0 05 mol/l, pH 8 2 for 20 min. Parti-
culate materials were eliminated by centri-
fugation at 100,000 g for 2 h. The super-
natants, designated as solubilized mnembrane
antigens (SMA), were dialysed overnight
against a 0-1 DOC solution. Protein con-
centration was determined by the Lowry et
al. (1951) method. Radioactive SMA were
prepared by acetylation with 3H-acetic
anhydride (specific activity 500 jCi/mmol)
by small scale modification of the technique
of Agrawal et al. (1968). The tumour
bearer serum was obtained by pooling sera
from animals with tumours 1-15 cm dia-
meter and kept at -40°C until required.
RESULTS
DOC solubilized membrane antigens
from both tumours did retain their
immunological properties, as shown by
their ability to induce and to react with
the corresponding specific antibodies (Co-
moglio and Forni, 1973; Bertini, Forni
and Comoglio, 1974). Six groups of 20
mice were inoculated every 48 h for 30
days with sera or SMA, or both, as
shown in the Table. With this inocula-
tion schedule a mean circulating dose of
1 + 0-1 mg/ml SMA was obtained, as
determined from the calculation of the
half-life of SMA labelled with 3H-acetic
anhydride. A similar scheme and the
same doses were adopted with ADK-lt.
It can be seen from Fig. 1 that neither
tumour take nor growth rate was in-
fluenced in any way by repeated injection
of MOPC-460 tumour bearer serum or
the presence of MOPC-460 SMA in the
circulating blood. The result was the
same even when the bearer serum and
MOPC-460 SMA were administered simul-
taneously. Figure 2 reveals a similar
picture for the ADK-lt experiment. Here
the tumour take percentage was reduced
to a value of 500, to increase the sensi-
tivity ofthe system.
Inoculation of treble doses of serum
and/or antigen also failed to show dif-
ferences between the various groups in
further experiments using groups of 6
animals and testing both tumours.
DISCUSSION
The results indicate that the pre-
existence and the passive administration
of serum from tumour bearing mice or
neoplastic cell membrane solubilized anti-
gens, whether singly or in association,
neither enhance nor depress the percentage
of takes or the growth rate of two trans-
plantable tumours in previously non-
immunized mice.
The tested tunmours possess tumour
specific antigens (Comoglio and Foriii,
1973; Bertini, Forni and Comoglio, 1974),
some of which can be employed to induce
resistance (Lynch et al., 1972; Cavallo and
Forni, 1974). Earlier work has also
indicated that the "take " of these
tumours is influenced by spontaneous or
artificially provoked changes in host
immune reactivity, suggesting that their
growth is hindered by a self-induced
mechanism of immunological type (Forni
and Comoglio, 1973). The pre-existence
TABLE-Inoculation Pattern* in Mice Challenged with MOPC-460
Grotip No. of mice Inoculum
A 20 0 * 3 ml normal mouise serum
B 20 0 :3 ml MOPC-460 bearer mouse serum
C 20 30 mg normal liver SMA
D 20 30 mg MOPC-460 SMA
E 20 0 :3 ml normal mouse serum preinctubated with
:30 mg MOPC-460 SMAt
F 20 0 3 ml MOPC-460 bearer mouse serum preinctu-
batecd with 30 mg MOPC-460 SMAt
Challenge with
2 x 105 MOPC-460 living cells
2 x 105 MOPC-460 living cells
2 x 105 MOPC-460 living cells
2 x 105 MOPC-460 living cells
2 x 105 MOPC-460 living cells
2 x 105 MOPC-460 living cells
* Inoculations were started 24 h before the challenge with neoplastic cells and were repeate(d at 48 h
intervals for 30 (lays.
t Pre-incuhation at :37 C for 10 mill before inoculation.
366EFFECT OF ANTIGENS AND SERUM ON TUMOUR GROWTH
100 -
80 -
60 -
40-
20 -
I I 1
5 id 15
A-DAYS AFTER
A~~~m.A af s 0 0 a va0
**
OJR
/A
20 25 30
CHALLENGE
15 20 . 25 30
B-OAYS AFTER CHALLENGE
FIG. 1.-Tumour incidence (A) and growth (B) in mice injected with 2 x 105 MOPC-460 cells. Groups of 20 mice inoculated every 48th h with: (0) 0-3 ml normal mouse serum; (0) 0-3 ml MOPO-460 bearer mouse serum; (O) 30 mg normal liver SMA; (-) 30 mg MOPC-460 SMA; (A) 0-3 ml normal mouse serum preincubated with 30 mg normal liver SMA; (A) 0-3 ml MOPC-460 bearer mouse serum preincubated with 30 mg MOPC-460 SMA. Vertical lines: ±standard deviation. Hatched area: mean values standard deviation for groups inoculated with normal
serum and/or normal liver SMA.
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FiG. 2.-Tumour incidence (A) and growth (B) in mice injected with 7 X 104 ADK-lt cells.
Groups of 20 mice inoculated every 48th h with: (0) 0-3 ml normal mouse ser$m; (0) 03 ml
ADK-lt bearer mouse serum; (H-1) 30 mg normal liver SMA; (-) 30 mg ADK-lt SMA; (A) 0*3 ml
normal mouse serum preincubated with 30 mg normal liver SMA; (A) 0 3 ml ADK-lt bearer mouse
serum preincubated with 30 mg ADK-lt SMA. Vertical lines: ± standard deviation. Hatched
area: mean values standard deviation for groups inoculated with normal seruri and/or normal
liver SMA.
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of serum factors during the first, critical
period of the tumour-host relationship
has no appreciable effect in situations of
this kind, which are comparable with
many occurring naturally in vivo.
These findings conflict with those
obtained in the in vitro system, where
sensitized lymphocyte activity is in-
hibited by soluble factors. Failure of
these substances to prove effective in our
experiment could be due to employment
of doses lying outside some narrow and
critical concentration range (Baldwin et
al., 1972, 1973). Dependence on concen-
tration should, however, be less dominant
in vivo since the blocking effect is main-
tained as the relation between antigen
and antibodies varies due to increase in
the neoplastic mass. Sub-threshold acti-
vity would appear to be excluded by the
fact that no differences were observed
when the challenge dose was altered, or
when administration doses were trebled.
Alternatively, the challenge dose could
be sufficient to induce the presence of
circulating blocking factors and all-or-
nothing enhancement of tumour growth.
The immunological relation between the
host and the developing tumour would
thus be unaffected by the administration
of further serum factors.
Other explanations may, of course, be
forthcoming. Nevertheless, it may fairly
be suspected from our findings that
serum blocking factors, in spite of their
undeniable effect in vitro and certain in
vivo contexts, may often fail to produce
significant changes in the naturally evolv-
ing development of host resistance to
tumour growth.
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